uniQure (QURE)
(Real Time Quote from BATS)
$4.86 USD
-0.28 (-5.45%)
Updated Sep 25, 2024 02:50 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
QURE 4.86 -0.28(-5.45%)
Will QURE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QURE
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
uniQure (QURE) Soars on New Huntington's Disease Study Data
Other News for QURE
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure treatment of Fabry disease granted orphan designation
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure announces dosing of first patient in Phase I/IIa trial of AMT-191
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and uniQure (QURE)